ClinicalTrials.gg
Active, not recruitingNCT05699603Updated Sep 24, 2025

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

A Phase 2 interventional study of Biopsy and Calcipotriene in Actinic Keratosis, sponsored by University of Arizona. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by University of Arizona · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing fluorouracil in Keratosis, Actinic — 3 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Keratosis, Actinic.

Planned enrollment
12th of 19
56 · median 60
Started
2024
with 1 other
Phase 2
Only one
of the 19
Registered
15th of 19
by date

Among the 19 studies testing fluorouracil in Keratosis, Actinic, this one is the 12th largest by planned enrollment, is one of 2 that started in 2024, is the only one in phase 2, and was the 15th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

3 of the 19 studies testing fluorouracil in Keratosis, Actinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluorouracil in Keratosis, Actinic, or all of them as a file.
02

Study summary

This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Solid organ transplant recipients are at high risk of developing skin cancer. Actinic keratosis (AK), is a premalignant skin lesion that can progress to squamous cell skin cancer. In this study, solid organ transplant recipients with multiple AKs are treated with topical calcipotriene and 5-FU to evaluate how effective this therapy is against AKs and if this could lower their risk of skin cancer. Topical calcipotriene is a form of vitamin D and is used to treat psoriasis. Prior research reported immunomodulatory effects in the skin induced by topical calcipotriene. Topical 5- fluorouracil is a chemotherapy agent and is one of the therapy options for multiple AKs in specific clinical scenarios. Prior research indicates that topical calcipotriene used together with topical 5-FU was more effective in treating multiple AKs than 5-FU alone in individuals with healthy immune system. This study is investigating now if similar beneficial effects can be seen in immunosuppressed individuals who are solid organ transplant recipients.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the induction of CD4+ TRM cells (CD3+CD4+CD103+) in the actinic keratosis at one day after completing one and two courses of calcipotriene plus 5-fluorouracil (5-FU) immunotherapy compared with before treatment.

SECONDARY OBJECTIVES:

I. To evaluate the persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK at 6 months after initiation of treatment compared with before treatment.

II. To evaluate the persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK at 6 months after initiation of treatment compared with after completing one and two courses of treatment.

III. To determine the percent reduction in the number of AKs on the treated areas at 8 weeks after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment.

IV. To determine the erythema extent and intensity scores of the treated anatomical sites at one day after the completion of one and two courses of calcipotriene plus 5-FU immunotherapy.

V. To determine differences in AK clearance between the treated anatomical sites (upper extremities versus [vs.] face vs. scalp).

VI. To assess the safety and tolerability of one and two courses of calcipotriene plus 5-FU treatment.

VII. To assess any incidence of biopsy-proven acute organ rejection of the graft.

EXPLORATORY OBJECTIVES:

I. To determine the percentage of participants with a new diagnosis of squamous cell carcinoma (SCC) on the treated anatomical sites at 6 months after the initiation of treatment compared with the identical duration prior to therapy.

II. To evaluate the persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK at 8 weeks after treatment with one and two courses of calcipotriene plus 5-FU compared with before treatment.

III. To evaluate the induction of TSLP, CD8+ TRM and natural killer (NK) cell infiltrates in the AK at one day after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment.

IV. To evaluate the induction of other immune cells/factors in the AK at one day after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment.

V. To determine the induction of TSLP, CD3+ T, CD4+ T, CD8+ TRM, NK cell and other immune cells/factors in the AK at one day after two courses compared with one day after one course of calcipotriene plus 5-FU immunotherapy.

VI. To evaluate the persistence of CD8+ TRM, NK cells in the AK at 8 weeks after treatment with one and two courses of calcipotriene plus 5-FU compared with before treatment.

VII. To evaluate the persistence of CD8+ TRM, NK cells in the AK at 6 months after initiation of treatment compared with before treatment. VIII. To compare the immune infiltrate in any SCC that develops over 6 months after one and two courses calcipotriene plus 5-FU immunotherapy with SCCs that developed before treatment using archived tumor samples.

IX. To evaluate the effect of number and type of field therapy and the number of cryotherapies after the trial, age, gender, history of immunosuppressive therapy, exposure to ionizing radiation or chemical carcinogens before and after transplantation, genetic factors (Fitzpatrick skin type I, II and III), pre-transplantation end-organ disease on SCC outcomes in OTRs.

X. To compare the immune induction outcomes in AKs versus the normal skin samples.

OUTLINE:

Participants receive calcipotriene plus 5-fluorouracil cream topically twice a day (BID) for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study. Patients who continue to experience AKs at week 8 may receive a second course of calcipotriene plus 5-fluorouracil cream topically BID for 6 consecutive days on study.

03

Conditions studied

  • Actinic Keratosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who had received a kidney or lung transplant >= 2 years before enrollment in the study with a stable status of transplanted graft (participants must have visited their transplant specialist within 6 months before enrolling to the study, documenting stable graft safety). The target population includes patients who are on tacrolimus and/or MMF without voriconazole as their regimen.
  • Presence of four to fifteen clinically typical, visible, and discrete AKs in 25 cm\^2 on any of the following anatomical sites: upper extremities, face, and/or scalp.
  • Age of at least 18 years. Because no dosing or adverse event (AE) data are currently available on the use of calcipotriene plus 5-FU in participants \<18 years of age, children and adolescents are excluded from this study but will be eligible for future pediatric trials, if applicable.
  • performance status >= 60%.
  • Leukocytes >= 3,000/microliter and \< 12000/ microliter.
  • >= 1,000/microliter.
  • >= 100,000/microliter.
  • Creatinine =\< 1.5 × institutional .
  • Baseline respiratory requirement for lung transplant recipients:

    • Respiratory rate within 12-18/min
    • PO2 saturation within 90-100mmHg
  • Female participants must be non- (i.e., by a history of age > 50 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, history of bilateral tubal ligation, or history of bilateral oophorectomy) OR must have a negative urine pregnancy test. The effects of calcipotriene plus 5-FU on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because of unknown teratogenic effect, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
  • Ability and willingness to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • OTRs with any sign of organ rejection are not eligible.
  • Patients who received any systemic cancer therapy or radiation within =\< 1 year (y) of study enrollment, or have a diagnosis requiring them to receive such treatment(s) are excluded.
  • Patients with known dihydropyrimidine dehydrogenase deficiency (due to the higher risk of 5-FU toxicity).
  • Patients with known history of hypercalcemia or vitamin D toxicity.
  • History of treatment with calcipotriene plus 5-FU within one year before enrollment in the study.
  • The treatment area is within 5 cm of an incompletely healed wound or a suspected basal cell or squamous cell carcinoma.
  • The treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or lesions that had not responded to repeated cryotherapy.
  • Participants may not be receiving any other agents.
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to calcipotriene and or 5-FU
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because there is an unknown but potential risk for teratogenic or abortifacient effects. Also, there is unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with calcipotriene plus 5-FU, breastfeeding should be discontinued if the mother is treated.
  • Participants who are -positive will be excluded from the study. There is a higher risk of organ rejection in HIV-positive patients, and also a higher risk of developing skin cancer, related to their infection-associated state and drug-induced immunosuppression for preventing organ rejection. In addition, considering HIV's adverse effects on CD4+ T cell function and the fact that the topical medication in this study is specifically designed to target CD4+ T cells, we plan to exclude HIV positive patients in order to avoid this confounding factor on the primary endpoint of the study.
  • Participants with known history of chronic , or will be excluded from the study in order to avoid confounding an existing condition with an immune response to the study agents.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Prevention (calcipotriene, fluorouracil)

    Participants receive calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study. Patients who continue to experience AKs at week 8 may receive a second course of calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study.

    Procedure: Biopsy · Drug: Calcipotriene · Drug: Fluorouracil

Interventions

  • ProcedureBiopsy

    Undergo skin biopsy

    Also known as: BIOPSY_TYPE, Bx

  • Applied topically

    Also known as: Calcipotriol, Dovonex

  • Applied topically

    Also known as: 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757

06

What researchers measure

Primary outcomes

  1. Induction of CD4+ TRM cells (CD3+CD4+CD103+) in the actinic keratosis

    Will be assessed at one day after completing one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment. Paired t test will be performed to evaluate whether the changes from baseline are significantly different from 0.

    Time frame: At one day after completing one and two courses of calcipotriene plus 5-FU immunotherapy

Secondary outcomes

  1. Persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK

    Will be assessed after initiation of treatment compared with after initiation of treatment compared with before treatment. The mean change from baseline at 8 weeks and 6 months, respectively, after one and two courses and the associated 95% CI will be reported for both AK and normal skin.

    Time frame: At 6 months

  2. Persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK

    Will be assessed after initiation of treatment compared with after completing one and two courses of treatment. The mean change from baseline at 8 weeks and 6 months, respectively, after one and two courses and the associated 95% CI will be reported for both AK and normal skin.

    Time frame: At 6 months

  3. Percent reduction in the number of AKs

    Will be assessed on the treated areas at 8 weeks after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment.

    Time frame: At 8 weeks

  4. Erythema extent and intensity scores of the treated anatomical sites

    Will be assessed at one day after the completion of one and two courses of calcipotriene plus 5-FU immunotherapy using the mean changes and the associated 95% CIs. The percentage of the participants with AK clearance (i.e., response to the treatment) and the exact (Clopper-Pearson) 95% CI will be reported by the treated anatomical sites.

    Time frame: At one day after the completion of one and two courses

  5. Differences in AK clearance

    Will be assessed between the treated anatomical sites (upper extremities vs. face vs. scalp).

    Time frame: At week 24

  6. Incidence of adverse events

    Will be assessed after of one and two courses of calcipotriene plus 5-FU treatment.

    Time frame: After of one and two courses of calcipotriene plus 5-FU treatment

  7. Incidence of biopsy-proven acute organ rejection of the graft

    The exact (Clopper-Pearson) 95% CI will be reported.

    Time frame: At week 24

Other outcomes

  1. Percentage of participants with new diagnosis of SCC on the treated anatomical sites

    Will be assessed after the initiation of treatment compared with the identical duration prior to therapy.

    Time frame: At 6 months

  2. Persistence of CD4+ TRM (CD3+CD4+CD103+) in the AK

    Will be assessed after treatment with one and two courses of calcipotriene plus 5-FU compared with before treatment.

    Time frame: At 8 weeks

  3. Induction of TSLP, CD8+ TRM and natural killer (NK) cell infiltrates in the AK

    Time frame: At one day after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment

  4. Induction of other immune cells/factors in the AK

    Time frame: At one day after one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment

  5. Induction of TSLP, CD3+ T, CD4+ T, CD8+ TRM, NK cell and other immune cells/factors in the AK

    Time frame: At one day after one and two courses of calcipotriene plus 5-FU immunotherapy

  6. Persistence of CD8+ TRM, NK cells in the AK

    Will be assessed after treatment with one and two courses of calcipotriene plus 5-FU compared with before treatment.

    Time frame: At 8 weeks

  7. Persistence of CD8+ TRM, NK cells in the AK

    Will be assessed after initiation of treatment compared with before treatment.

    Time frame: At 6 months

  8. Compare the immune infiltrate in any SCC

    Will be assessed after one and two courses calcipotriene plus 5-FU immunotherapy with SCCs that developed before treatment using archived tumor samples.

    Time frame: At 6 months

  9. Effect of number and type of field therapy and the number of cryotherapies

    Will be assessed after the trial, age, gender, history of immunosuppressive therapy, exposure to ionizing radiation or chemical carcinogens before and after transplantation, genetic factors (Fitzpatrick skin type I, II and III), pre-transplantation end-organ disease on SCC outcomes in organ transplant recipients (OTRs).

    Time frame: Up to 2 years

  10. Comparison of the immune induction outcomes in AKs versus the normal skin samples

    Time frame: Up to 6 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Feb 2027, 30 months after the start.

Of 18 phase 2 interventional studies under Keratosis, Actinic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Jan 26, 2023
StartActual
Jul 2, 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2029
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05699603
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Jul 2, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Sep 24, 2025

Study contacts

Shadmehr Demehri
principal investigator · University of Arizona Cancer Center - Prevention Research Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Fluorouracil

Start the discussion